KPV

Little activity

KPV appears in 64 indexed publications going back to 1984, including 3 in the past twelve months. No clinical trials are registered on ClinicalTrials.gov.

64
Indexed publications
3
Past 12 months, against 3 the year before
0
Registered clinical trials
Monthly readers on Wikipedia

On This Figure
A three-letter sequence code, so a peptide context filter is required to exclude unrelated abbreviations.

Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
20151
20161
20172
20181
20192
20201
20211
20220
20230
20243
20251
20263
Public Attention

Who is looking it up

Monthly readers of the KPV article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

Not enough attention history yet for a trend line.

Clinical Trials

The registered pipeline

No clinical trials are registered for this compound on ClinicalTrials.gov. That is common for peptides with no remaining composition of matter patent: without exclusivity there is rarely a sponsor to fund registered trials, so the evidence stays preclinical.

References

Most recent work

The newest indexed records mentioning KPV, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

  1. 2026-03-25·The Journal of sports medicine and physical fitness

    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review

    Coutinho LFD, DE Oliveira Neves LF, Camilo RP. et al.

  2. 2026-04-28·Cytotechnology

    Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells

    Lee JY, Lee J, Jung WK et al.

  3. 2026-01-14·Science advances

    Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers

    Cheng J, Wu P, Li C et al.

  4. 2025-03-06·Tissue & cell

    Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway

    Sung J, Ju SY, Park S et al.

  5. 2024-09-10·Advanced healthcare materials

    KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy

    Zhang L, Li D, Aierken Y et al.

  6. 2023-10-11·Bioactive materials

    A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment

    Marotti V, Xu Y, Bohns Michalowski C et al.

  7. 2024-08-15·Frontiers in pharmacology

    PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS

    Zhang D, Jiang L, Yu F et al.

  8. 2021-10-18·ACS nano

    Biomimetic Melanosomes Promote Orientation-Selective Delivery and Melanocyte Pigmentation in the H2O2-Induced Vitiligo Mouse Model

    Sun MC, Xu XL, Du Y et al.

In the Catalogue

KPV available from Polaris Research

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-08-02.